Cell-Based Complement Activity Evaluation

Creative Biolabs offers cell-based complement activity evaluation services designed to help researchers characterize how therapeutic antibodies, biologics, nanoparticles, engineered cells, and disease-relevant targets interact with the complement system in biologically meaningful cellular settings.

Submit Your Request Now

Download our service brochure

Inquiry

Why Cell-Based Complement Activity Evaluation Matters

While purified-protein assays are useful for dissecting individual mechanisms, they cannot fully recapitulate the complexity of complement activation on a living cell surface. Cell-based systems, by contrast, allow investigators to measure complement engagement where it actually matters: at the interface of target membrane composition, antibody binding geometry, serum components, and endogenous complement regulators.

Our cell-based complement activity platform can be configured to assess classical-, lectin-, and alternative-pathway contributions, quantify surface deposition of complement fragments, evaluate terminal pathway progression, and connect upstream activation signals with downstream biological outcomes such as cell lysis, opsonization, and protection by inhibitors. By integrating assay design, optimized controls, pathway-resolved conditions, and robust analytics, Creative Biolabs delivers a clear picture of complement function in your model system.

Great Minds Choose Creative Biolabs

Partner with Us

What We Test

Antibody-Mediated Complement Activation on Target Cells

We evaluate how monoclonal antibodies, bispecifics, Fc-engineered molecules, and other targeted biologics engage complement on antigen-positive cells. By measuring complement activity directly on target cells, we help determine whether molecular design differences translate into functional complement engagement.

Complement-Dependent Cytotoxicity Readiness

For programs pursuing CDC as a key mechanism of action, we assess complement activation together with lytic endpoints to determine whether upstream engagement progresses to meaningful target-cell killing.

Cell Therapy Compatibility and Protection Studies

We investigate whether primary cells, engineered cell lines, stem cell-derived products, or donor-derived cellular therapeutics are vulnerable to serum complement attack. These studies can reveal baseline susceptibility, compare manufacturing lots, and evaluate protective strategies.

Disease-Relevant Surface Activation Models

Cells exposed to stress, apoptosis, oxidative injury, inflammatory cytokines, or immune complex deposition may display altered complement sensitivity. We design assays around these states to examine how disease-associated surface changes affect complement initiation, amplification, and terminal pathway activation.

Complement Inhibitor Screening in Cellular Context

Our service helps rank inhibitors, antibodies, peptides, and biologics under biologically relevant conditions by measuring their ability to reduce deposition, suppress lysis, or shift pathway-specific activity on live or fixed cellular targets.

Nanoparticle and Surface Interaction Studies

We also support projects involving cell-associated biomaterials, particles, membrane-coated systems, or delivery platforms that interact with cells in the presence of serum. Such studies can uncover complement-triggering liabilities and identify mitigation strategies before more costly downstream development.

Host–Pathogen and Immune Evasion Research

Pathogens and pathogen-mimetic systems often modulate complement deposition on host or microbial surfaces. We evaluate complement activity in infection-related models to support immune-evasion research, vaccine studies, and therapeutic discovery programs focused on host defense and inflammatory control.

Discuss Your Needs

Assay Formats

Flow Cytometry-Based Complement Activity Assessment

For suspension cells, adherent-cell derivatives, immune cells, tumor cells, primary cells, and mixed cellular populations

Plate-Based Cell-Associated Complement Assays

For a high number of candidates must be screened against a defined target under matched conditions

Imaging-Enabled Cell Surface Complement Studies

For projects requiring visual confirmation of complement localization

Cell Models We Commonly Support

We work with a broad range of cell types and can adapt protocols based on cell fragility, antigen level, serum compatibility, and the required endpoint.

Tumor Cell Lines - Useful for oncology and CDC-focused antibody programs, especially where target density and complement regulator expression influence outcome.
Primary Immune Cells - Suitable for depletion strategies, immune modulation studies, and donor-specific analyses.
Stem Cell-Derived and Engineered Cells - Applicable to regenerative medicine, cell therapy, and translational compatibility studies.
Epithelial and Endothelial Models - Relevant in inflammatory, renal, vascular, pulmonary, and barrier-related complement research.
Erythrocyte, Platelet, or Blood-Associated Models - Valuable for hemolysis-linked biology, transfusion research, and hematologic complement studies.
Infected, Stressed, or Cytokine-Primed Cells - Designed to mimic disease-associated surfaces that alter complement susceptibility or activation profile.
Client-Supplied Custom Models - We welcome client-specific cell lines, engineered targets, transfectants, and specialized biological systems when accompanied by handling guidance and project goals.

Design Your Protocol

Species & Matrices

Species

We support complement activity evaluation using:

Human serum, including pooled normal human serum or donor-specific serum
Non-human primate serum for translational bridging
Mouse and rat systems for preclinical relevance
Other species upon feasibility review

Matrices

Common matrices include:

Serum, generally preferred for complement activation studies
Citrate plasma, where compatible with project goals and endpoint interpretation
Reconstituted or pathway-modified buffer systems
Depleted sera for pathway dissection
Reconstituted sera for mechanistic confirmation

Depleted and Customized Panels

To clarify pathway contribution or target dependency, we can incorporate:

C1q-depleted serum, C2-depleted serum, C3-depleted serum
Factor B-depleted serum, factor D-perturbed or pathway-biased formats
Reconstitution with purified components, heat-inactivated controls
Inhibitor-spiked comparative conditions

Core Readouts Available in Our Cell-Based Platform

Our cell-based complement activity evaluation service can be structured around one or several complementary endpoints.

Readouts	Descriptions
Surface Complement Fragment Deposition	We quantify the deposition of key complement fragments such as C3b, iC3b, C4b, C4d, C3d, or terminal complex-associated markers on the cell surface. These measurements are especially valuable for understanding whether activation has been initiated, amplified, or stabilized on the target.
Terminal Pathway Progression	When the research goal requires insight into lytic competence, we assess progression into terminal pathway activity. This can include membrane attack complex-related deposition and correlations with functional cell injury.
Complement-Dependent Cytotoxicity	For cell-killing programs, we measure lysis or viability change following complement activation. Depending on the model, this may involve dye release, viability staining, metabolic readouts, or flow-cytometric discrimination of dead and live populations.
Opsonization and Phagocytic Relevance	In some programs, complement function is valuable not because it lyses the cell directly, but because it marks the target for immune recognition. In those cases, deposition-focused assays help estimate opsonization strength and support follow-on studies involving phagocytic or myeloid effector systems.
Inhibitor Potency and Mechanism in Complex Matrices	We compare inhibitor candidates in the presence of intact serum and membrane-bound targets to determine how robustly they suppress complement activation under near-physiological conditions. This is especially informative when serum proteins, competing ligands, or cell-surface regulators are expected to influence performance.
Pathway Bias and Mechanistic Resolution	By changing serum conditions, depletion/reconstitution formats, activator context, or blocking reagents, we can help determine whether observed activity is primarily classical, lectin, alternative, or mixed-pathway in origin.

Design Your Customization

Case Studies

Case 1

Modeling complement activation on human glomerular microvascular endothelial cells

The glomerular microvascular endothelial cells (GMVECs) are the primary target of AP activation in aHUS, but the exact mechanisms behind this high susceptibility of GMVECs to complement deposition remains unknown. The aim of this study was to model complement activation in aHUS patients ex vivo, by measuring complement deposition on human conditionally immortalized GMVECs (ciGMVECs). Moreover, by having the unique possibility to create a ciGMVEC line derived from an aHUS patient, the researchers could model the complement activation in samples of an aHUS patient on patient's own endothelial cells.

Comparing complement C5b-9 deposition on glomerular endothelial cells. (OA Literature) Fig. 1 Serum-induced C5b-9 deposition on primary glomerular microvascular endothelial cells (GMVECs) and conditionally immortalized GMVECs (ciGMVECs).^1,2

References

Stevens, Kes H., et al. "Modeling complement activation on human glomerular microvascular endothelial cells." Frontiers in immunology 14 (2023): 1206409. https://doi.org/10.3389/fimmu.2023.1206409
Distributed under Open Access license CC BY 4.0, without modification.

What Our Clients Say

We needed a cell-based complement assay that could distinguish meaningful functional differences between closely related candidates. Their team helped us refine the study design, select appropriate controls, and interpret the results in a way that directly supported our lead selection process. The final dataset was clear, well organized, and highly informative."

— Senior Scientist, Immuno-Oncology Biotech Company

"Our project involved a custom cell model and required more than a standard off-the-shelf assay. Creative Biolabs was flexible in adapting the workflow to our system, and they provided useful feedback on variables that could affect complement readouts. Their ability to customize the assay while maintaining strong quality control gave us confidence in the data."

— Principal Investigator, Academic Research Institute

"The project moved efficiently, communication was prompt, and the scientific rigor of the work was evident throughout. We appreciated the team's attention to controls, assay optimization, and data presentation. This was not just a service provider relationship—they felt like a knowledgeable extension of our own research team."

— Associate Director, Therapeutic Antibody Development

"Complement assays can be difficult to interpret, especially when multiple biological variables are involved. Creative Biolabs provided a well-controlled cellular assay package and helped us connect upstream deposition results with downstream functional outcomes. Their team clearly understands how to translate complex complement biology into actionable project insights."

— R&D Manager, Mid-Size Biotech Company

Frequently Asked Questions

How is a cell-based complement assay different from a purified complement assay?

Purified or plate-based assays are excellent for mechanistic reductionism and target-specific questions, but they do not fully capture the biological behavior of complement on living cell surfaces. Cell-based assays reflect membrane composition, antigen density, regulator expression, and cell-state effects, all of which can significantly alter complement outcomes.

Which endpoint should I choose first: deposition or lysis?

That depends on your biological question. If you need to know whether complement is engaging the target at all, deposition is often the most informative starting point. If your goal is direct effector function, such as CDC, a lysis readout should be included. Many programs benefit from measuring both, because strong upstream activity does not always lead to terminal pathway progression.

What if my cells express complement regulatory proteins?

That is common and often biologically important. Cell-surface regulators can significantly reduce terminal pathway progression even when upstream deposition is strong. We can incorporate study elements that clarify whether regulator expression is limiting your endpoint and whether a candidate can overcome or bypass that protection.

What sample types work best?

Serum is generally preferred for complement activation studies, and viable target cells are critical for cell-based work. Antibodies, inhibitors, proteins, and custom reagents can also be incorporated. We provide project-specific guidance before study initiation.

Can you combine this with CDC, C1q, or terminal pathway assays?

Absolutely. Many clients request integrated packages that connect upstream recruitment, intermediate deposition, and downstream function. This often produces a far clearer development story than any single endpoint alone.

What does the final report include?

Reports typically include methods, conditions, controls, figures, processed results, and interpretation. We aim to present not only what happened in the assay, but what the data mean for your program and which next steps may be most informative.